Randomised Study of Axitinib (Axi) Plus Best Supportive Care (Bsc) Versus Placebo (Pbo) Plus Bsc in Patients with Advanced Hepatocellular Carcinoma (Hcc) Following Prior Antiangiogenic Therapy

Annals of Oncology - Tập 25 - Trang v1 - 2014
Y-K. Kang1,2, T. Yau3,2, J-W. Park4, E. Boucher5, H.Y. Lim6, R.T.P. Poon7, T-Y. Lee8, S. Obi9, S.L. Chan10, S.K. Qin11, R.D. Kim12, J. Tang13, O. Valota14, D. Chakrabarti15, M. Kudo16
1Oncology, Asan Medical Center, University of Ulsan, Seoul, KOREA
2Equal contribution
3Medicine, Centre for Cancer Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, CHINA
4Center for Liver Cancer, National Cancer Center, Goyang, KOREA
5Medical Oncology, Centre Eugène Marquis, Rennes, France
6Hematology-oncology, Samsung Medical Center, Sungkyunkwan University, Seoul, KOREA
7Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, CHINA
8Gastroenterology and Hepatology, Taichung Veterans General Hospital, Taichung City, TAIWAN
9Hepatology, Sasaki Foundation Kyoundo Hospital, Tokyo, JAPAN
10Clinical Oncology, Prince of Wales Hospital, Hong Kong, China
11PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, CHINA
12Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
13Oncology Business Unit, Pfizer Inc, New York, NY, USA
14Clinical Oncology, Pfizer Italia SRL, Milan, ITALY
15Oncology, Pfizer Inc, Collegeville, PA, USA
16Gastroenterology and Hepatology, Kinki University Hospital, Osaka, JAPAN

Thông tin
Thông tin xuất bản

Annals of Oncology

Tập 25

v1

Thông tin tác giả